Lexicon Pharmaceuticals, Inc. (LXRX)
Nasdaq: LXRX · Pharmaceutical Preparations · The Woodlands, TX · filing with the SEC since 2000
Who owns Lexicon Pharmaceuticals, Inc.
As filed with the SECHolders of 5% or more
2
Artal Participations S.a r.l. holds 39.4% of Common Stock, par value $0.001 per share, as its SCHEDULE 13D/A filed May 8, 2026 says.
Directors and officers
26
report now, of 50 people on the record since 2006. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 2 named at left.
Holders of 5% or moreshare of the class, as filed
Artal Participations S.a r.l.
SCHEDULE 13D/A · filed May 8, 2026 · Common Stock, par value $0.001 per share · 36.2% in Feb 2, 2026
Fmr LLC
SCHEDULE 13G/A · filed Aug 6, 2026 · COMMON STOCK · 10.5% in Jul 8, 2025
What LXRX reports owning in othersstakes of 5% or more, and other ties
Lexicon Pharmaceuticals, Inc. reports no stake in another company in the record.
Insider tradesForm 4
0sales
9purchases
0sales on a scheduled plan
0people selling
$0sold, in dollars
$2.8Mbought, in dollars
Open-market trades on Form 4 from Nov 9, 2025 to Nov 9, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 9, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window3 of 50 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Debbane Raymond | director | 0 | $0 | 0 | 7 | $700,000 |
| Exton Michael | Chief Executive Officer | 0 | $0 | 0 | 1 | $0 |
| Artal Group S.A. | director | 0 | $0 | 0 | 1 | $2.0M |